Ixazomib citrateProduct ingredient for Ixazomib

Name
Ixazomib citrate
Drug Entry
Ixazomib

Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration.

Accession Number
DBSALT001605
Structure
Synonyms
Not Available
UNII
46CWK97Z3K
CAS Number
1239908-20-3
Weight
Average: 517.12
Monoisotopic: 516.087366
Chemical Formula
C20H23BCl2N2O9
InChI Key
MBOMYENWWXQSNW-AWEZNQCLSA-N
InChI
InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-19(32)20(34-21,7-16(27)28)8-17(29)30)25-15(26)9-24-18(31)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,31)(H,25,26)(H,27,28)(H,29,30)/t14-/m0/s1
IUPAC Name
2-[4-(carboxymethyl)-2-[(1R)-1-{2-[(2,5-dichlorophenyl)formamido]acetamido}-3-methylbutyl]-5-oxo-1,3,2-dioxaborolan-4-yl]acetic acid
SMILES
CC(C)C[C@H](NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1
ChemSpider
26286874
ChEBI
90939
ChEMBL
CHEMBL3545432
ZINC
ZINC000200299610
Wikipedia
Ixazomib
Predicted Properties
PropertyValueSource
Water Solubility0.0085 mg/mLALOGPS
logP1.9ALOGPS
logP2.99Chemaxon
logS-4.8ALOGPS
pKa (Strongest Acidic)3.49Chemaxon
pKa (Strongest Basic)-1.8Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area168.33 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity112.91 m3·mol-1Chemaxon
Polarizability49.14 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon